Patents by Inventor Alan D. Cardin
Alan D. Cardin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7875596Abstract: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or 3-O positions of the uronic acid and glucosamine saccharide residues. Particularly effective dermatan sulfate HIT antagonists have a mean molecular weight of from about 2000 to about 10,000 Daltons.Type: GrantFiled: January 16, 2008Date of Patent: January 25, 2011Assignee: Celsus Biopharmaceuticals, Inc.Inventor: Alan D. Cardin
-
Publication number: 20080138380Abstract: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or 3-O positions of the uronic acid and glucosamine saccharide residues. Particularly effective dermatan sulfate HIT antagonists have a mean molecular weight of from about 2000 to about 10,000 Daltons.Type: ApplicationFiled: January 16, 2008Publication date: June 12, 2008Applicant: Celsus Biopharmaceuticals, Inc.Inventor: Alan D. Cardin
-
Patent number: 6518244Abstract: Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.Type: GrantFiled: March 9, 2001Date of Patent: February 11, 2003Assignee: IntimaX CorporationInventors: Alan D. Cardin, Cornelius L. Van Gorp
-
Patent number: 6409987Abstract: A selectively targeted agent comprising a dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units that is covalently attached or bonded to a radioactive metal-ion binding moiety. The targeted agent is useful in preparing radiagnostic and/or radiopharmaceutical agents for diagnostic and/or therapeutic treatment when combined with an appropriate radioactive metal ion such as 99mTc, 186Re or 188Re.Type: GrantFiled: April 6, 2000Date of Patent: June 25, 2002Assignee: Intimax CorporationInventors: Alan D. Cardin, Cornelius L. Van Gorp
-
Publication number: 20010036932Abstract: Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.Type: ApplicationFiled: March 9, 2001Publication date: November 1, 2001Inventors: Alan D. Cardin, Cornelius L. Van Gorp
-
Patent number: 6232349Abstract: The oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are, pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: January 7, 1993Date of Patent: May 15, 2001Assignees: Merrell Pharamaceuticals Inc, The Dow Chemical CompanyInventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 6086864Abstract: The oligomers of the present invention are polythioureas having 3 to 50 recurring units derived from aromatic diamines substituted with anionic groups, and having a number average molecular weight of less than 10,000. These oligomers are water-soluble, preferably have a rigid backbone, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS.Type: GrantFiled: November 26, 1997Date of Patent: July 11, 2000Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical Co.Inventors: Michael J. Mullins, William A. Fordyce, William J. Kruper, Norton P. Peet, Alan D. Cardin
-
Patent number: 6013251Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.Type: GrantFiled: April 1, 1997Date of Patent: January 11, 2000Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, William A. Fordyce, Michael J. Mullins, Thomas A. Chamberlin, Michael J. Fazio
-
Patent number: 5986044Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.Type: GrantFiled: November 26, 1997Date of Patent: November 16, 1999Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Michael J. Mullins, William A. Fordyce, Thomas A. Chamberlin, Michael J. Fazio
-
Patent number: 5932614Abstract: Sulfonic acid stilbenes block the infection of cells by HIV and these compounds can be used to prevent viral infection.Type: GrantFiled: November 5, 1996Date of Patent: August 3, 1999Assignee: Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, A. Stanley Tyms
-
Patent number: 5861383Abstract: Various peptides having affinity for sulfated polysaccharides such as heparin, dextran sulfate and Pentosan polysulfate are bound to resins and used in affinity chromatography to prepare anti-HIV sulfated polysaccharides.Type: GrantFiled: September 4, 1996Date of Patent: January 19, 1999Assignee: Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson
-
Patent number: 5728731Abstract: The oligomers of the present invention are polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical Co.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5728874Abstract: The present invention relates to achiral polyurea oligomers, their uses and formulations as anti-HIV pharmaceuticals and to a process for the preparation of narrow mono- and polydispersed oligomers as an emodiment of the invention. The achiral oligomers are derived from repeating units of the monomer 4,4'-diamino-biphenyl-3,3'-disulfonic acid and are water soluble, have a rigid backbone, possess ordered anionic spacing and have a number average molecular weight of <20,000. The process relates to the synthesis of narrow poly- and mono-dipersed oligomers comprising the steps of: 1) restricting the crude olydispersed anionic oligomer mixture to a narrow polydispersed anionic oligomer mixture to a narrow polydispersed anionic oligomer mixture; and/or 2) isolating the monodispersed anionic oligomer; and 3) optionally converting the narrow poly- or mono-dispersed anionic oligomer salt from Step 1 or 2 to a desired pharmaceutically-acceptable salt, especially a solim or potassium salt.Type: GrantFiled: December 27, 1993Date of Patent: March 17, 1998Assignees: Merrell Pharmaceuticals, Inc., The Dow Chemical Co.Inventors: Michael J. Mullins, Ray E. Drumright, Alan D. Cardin, Norton P. Peet
-
Patent number: 5707615Abstract: The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: April 1, 1997Date of Patent: January 13, 1998Assignee: Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5672625Abstract: Sulfonic acid stilbenes block the infection of cells by HSV and CMV and these compounds can be used to treat viral infection.Type: GrantFiled: June 5, 1995Date of Patent: September 30, 1997Assignee: Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, A. Stanley Tyms
-
Patent number: 5670143Abstract: The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: May 19, 1995Date of Patent: September 23, 1997Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical CompanyInventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5670144Abstract: The oligomers of the present invention are polyesters having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: June 6, 1995Date of Patent: September 23, 1997Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical CompanyInventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5571505Abstract: The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: May 19, 1995Date of Patent: November 5, 1996Assignees: The Dow Chemical Company, Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5547992Abstract: The oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: March 21, 1995Date of Patent: August 20, 1996Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5512177Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moities which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.Type: GrantFiled: November 22, 1993Date of Patent: April 30, 1996Assignees: The Dow Chemical Co., Merrell Dow Pharmaceuticals Inc.Inventors: Alan D. Cardin, Michael J. Mullins, William A. Fordyce, Thomas A. Chamberlin, Michael J. Fazio